Njira Lugogo, MD

Njira Lugogo, MD, from University of Michigan.

Articles by Njira Lugogo, MD

AIRCULES: Lunsekimig Benefit Scales With Severity, With Njira Lugogo, MD

ByNjira Lugogo, MD

September 9th 2026

Phase 2b subgroup data showed lunsekimig's exacerbation benefit scaled with asthma severity and biomarker levels.

STAT6 Degraders: Accessible Biologic-Like Asthma Care? With Njira Lugogo, MD

ByNjira Lugogo, MD

September 9th 2026

Lugogo, ofUniversity of Michigan, discusses how oral STAT6 degraders like KT-621 could expand biologic-like asthma treatment beyond highest severity.

Tezepelumab Reduces Severe Asthma Exacerbations by 70% in Phase 4 PASSAGE

ByNjira Lugogo, MD

June 8th 2026

Phase 4 PASSAGE data from ATS 2026 show tezepelumab reduced exacerbation rates across a diverse real-world cohort, including smokers, adolescents, and patients with comorbid COPD.

HCPLive Five: Asthma Updates at ATS 2026

ByNjira Lugogo, MD,Brittany Duchene, MD,Simon Couillard, MD,Christian Cardillo, MD,Michael Wechsler, MD, MSc

June 4th 2026

5 interviews. 5 minutes. The asthma data from ATS 2026 your patients will be asking about.

Tezepelumab Reduced Severe Asthma Across Phenotypes in Phase 4 PASSAGE

ByNjira Lugogo, MD

May 26th 2026

At ATS 2026, Njira Lugogo, MD, discussed PASSAGE data showing tezepelumab reduced severe asthma exacerbations in smokers and patients with comorbid COPD.